265 related articles for article (PubMed ID: 9025764)
1. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
2. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
3. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
5. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
6. (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Med Chem; 1994 Oct; 37(21):3655-62. PubMed ID: 7932592
[TBL] [Abstract][Full Text] [Related]
7. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
[No Abstract] [Full Text] [Related]
11. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.
Smets LA; Loesberg C; Janssen M; Metwally EA; Huiskamp R
Cancer Res; 1989 Jun; 49(11):2941-4. PubMed ID: 2720653
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
14. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
Vaidyanathan G; Affleck DJ; Alston KL; Welsh P; Zalutsky MR
Nucl Med Commun; 2004 Sep; 25(9):947-55. PubMed ID: 15319601
[TBL] [Abstract][Full Text] [Related]
15. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
16. Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells.
Babich JW; Graham W; Fischman AJ
Eur J Nucl Med; 1997 May; 24(5):538-43. PubMed ID: 9142735
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
[TBL] [Abstract][Full Text] [Related]
19. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells.
Smets LA; Janssen M; Rutgers M; Ritzen K; Buttenhuis C
Int J Cancer; 1991 Jun; 48(4):609-15. PubMed ID: 2045205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]